Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.

Matsuo K, Huang Y, Zivanovic O, Shimada M, Machida H, Grubbs BH, Roman LD, Wright JD.

Gynecol Oncol. 2019 Jul 3. pii: S0090-8258(19)31337-X. doi: 10.1016/j.ygyno.2019.06.021. [Epub ahead of print]

PMID:
31279493
2.

Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.

Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA, Long Roche KC, Sonoda Y, Hensley ML, O'Cearbhaill RE, Chi DS, Alektiar KM, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol. 2019 Jun 12. pii: S0090-8258(19)31259-4. doi: 10.1016/j.ygyno.2019.05.015. [Epub ahead of print]

PMID:
31200927
3.

Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.

Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP.

Gynecol Oncol. 2019 Jul;154(1):144-149. doi: 10.1016/j.ygyno.2019.05.004. Epub 2019 May 18.

PMID:
31113680
4.

Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.

Filippova OT, Chi DS, Long Roche K, Sonoda Y, Zivanovic O, Gardner GJ, Tew WP, O'Cearbhaill R, Sarraf S, Sun SW, Alexander K, Korc-Grodzicki B, Shahrokni A.

Gynecol Oncol. 2019 Jul;154(1):77-82. doi: 10.1016/j.ygyno.2019.04.683. Epub 2019 May 8.

PMID:
31078241
5.

Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.

Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS.

Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23.

PMID:
31015198
6.

Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program.

Feit NZ, Goldman DA, Smith E, Deighan J, Iasonos A, Zivanovic O, Hyman DM.

JAMA Oncol. 2019 Feb 28. doi: 10.1001/jamaoncol.2018.7002. [Epub ahead of print] No abstract available.

7.

A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.

Tanner EJ, Filippova OT, Gardner GJ, Long Roche KC, Sonoda Y, Zivanovic O, Fischer M, Chi DS.

Gynecol Oncol. 2018 Dec;151(3):433-437. doi: 10.1016/j.ygyno.2018.10.006. Epub 2018 Oct 16.

PMID:
30336947
8.

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS.

J Clin Oncol. 2018 Oct 5:JCO1800454. doi: 10.1200/JCO.18.00454. [Epub ahead of print]

PMID:
30289732
9.

It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.

Zivanovic O, Chi DS, Filippova O, Randall LM, Bristow RE, O'Cearbhaill RE.

Gynecol Oncol. 2018 Dec;151(3):555-561. doi: 10.1016/j.ygyno.2018.09.007. Epub 2018 Sep 22. Review.

PMID:
30249527
10.

Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?

Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, Polen-De C, Gardner GJ, Sonoda Y, Zivanovic O, Abu-Rustum NR, Long Roche K, Chi DS.

Gynecol Oncol. 2018 Oct;151(1):24-31. doi: 10.1016/j.ygyno.2018.08.014. Epub 2018 Aug 17.

PMID:
30126704
11.

Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage Ib1 Cervical Cancer.

Tseng JH, Aloisi A, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum NR, Leitao MM Jr.

Int J Gynecol Cancer. 2018 Sep;28(7):1350-1359. doi: 10.1097/IGC.0000000000001319.

PMID:
30036225
12.

Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.

Tseng JH, Aloisi A, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol. 2018 Jul;150(1):44-49. doi: 10.1016/j.ygyno.2018.04.571.

13.

Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.

Oseledchyk A, Gennarelli RL, Leitao MM Jr, Aghajanian CA, Iasonos A, Zivanovic O, Zamarin D.

Cancer Med. 2018 Jun;7(6):2280-2287. doi: 10.1002/cam4.1447. Epub 2018 Apr 17.

14.

Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP).

Ko EM, Havrilesky LJ, Alvarez RD, Zivanovic O, Boyd LR, Jewell EL, Timmins PF 3rd, Gibb RS, Jhingran A, Cohn DE, Dowdy SC, Powell MA, Chalas E, Huang Y, Rathbun J, Wright JD.

Gynecol Oncol. 2018 May;149(2):232-240. doi: 10.1016/j.ygyno.2018.02.010. Epub 2018 Mar 13.

PMID:
29544708
15.

Ovarian Cancer Treatment - Are We Getting Warmer?

Spriggs DR, Zivanovic O.

N Engl J Med. 2018 Jan 18;378(3):293-294. doi: 10.1056/NEJMe1714556. No abstract available.

PMID:
29342385
16.

Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study.

Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL.

Am J Obstet Gynecol. 2018 Jan;218(1):109.e1-109.e11. doi: 10.1016/j.ajog.2017.09.026. Epub 2017 Oct 14.

17.

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, Zivanovic O.

Ann Oncol. 2017 Dec 1;28(12):2985-2993. doi: 10.1093/annonc/mdx525.

18.

Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer.

Cybulska P, Schiavone MB, Sawyer B, Gardner GJ, Zivanovic O, Brown CL, Jewell EL, Sonoda Y, Barakat RR, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol. 2017 Nov;147(2):371-374. doi: 10.1016/j.ygyno.2017.09.005. Epub 2017 Sep 22.

19.

Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.

Cowan RA, Tseng J, Murthy V, Srivastava R, Long Roche KC, Zivanovic O, Gardner GJ, Chi DS, Park BJ, Sonoda Y.

Gynecol Oncol. 2017 Nov;147(2):262-266. doi: 10.1016/j.ygyno.2017.09.001. Epub 2017 Sep 6.

20.

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, Sala E, Merghoub T, Snyder A, Miller ML.

Cell. 2017 Aug 24;170(5):927-938.e20. doi: 10.1016/j.cell.2017.07.025.

21.

Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery.

Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2017 Oct;147(1):115-119. doi: 10.1016/j.ygyno.2017.07.010. Epub 2017 Jul 19.

22.

Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.

Eriksson AGZ, Graul A, Yu MC, Halko A, Chi DS, Zivanovic O, Gardner GJ, Sonoda Y, Barakat RR, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol. 2017 Aug;146(2):263-267. doi: 10.1016/j.ygyno.2017.05.022. Epub 2017 May 17.

PMID:
28527673
23.

Lithium: A classic drug-Frequently discussed, but, sadly, seldom prescribed!

Zivanovic O.

Aust N Z J Psychiatry. 2017 Sep;51(9):886-896. doi: 10.1177/0004867417695889. Epub 2017 Apr 12. Review.

PMID:
28403623
24.

A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer.

Eriksson AG, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, Long Roche K, Sonoda Y, Leitao MM Jr, Jewell EL.

Int J Gynecol Cancer. 2017 May;27(4):743-747. doi: 10.1097/IGC.0000000000000959.

25.

Risk-reducing salpingectomy: Let us be opportunistic.

Long Roche KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O.

Cancer. 2017 May 15;123(10):1714-1720. doi: 10.1002/cncr.30528. Epub 2017 Mar 23. Review.

26.

A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.

Cowan RA, Eriksson AGZ, Jaber SM, Zhou Q, Iasonos A, Zivanovic O, Leitao MM Jr, Abu-Rustum NR, Chi DS, Gardner GJ.

Gynecol Oncol. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010. Epub 2017 Mar 9.

PMID:
28285846
27.

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):15-20. doi: 10.1016/j.ygyno.2017.02.023. Epub 2017 Feb 21.

28.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

29.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.

Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.

30.

Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.

Cowan RA, O'Cearbhaill RE, Zivanovic O, Chi DS.

Int J Hyperthermia. 2017 Aug;33(5):548-553. doi: 10.1080/02656736.2017.1283066. Review.

31.

Early diagnosis of genital mucosal melanoma: how good are our dermoscopic criteria?

Rogers T, Pulitzer M, Marino ML, Marghoob AA, Zivanovic O, Marchetti MA.

Dermatol Pract Concept. 2016 Oct 31;6(4):43-46. eCollection 2016 Oct.

32.

Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.

Yang C, Arnold AG, Trottier M, Sonoda Y, Abu-Rustum NR, Zivanovic O, Robson ME, Stadler ZK, Walsh MF, Hyman DM, Offit K, Zhang L.

Breast Cancer Res Treat. 2016 Dec;160(3):447-456. doi: 10.1007/s10549-016-4021-7. Epub 2016 Oct 18.

33.

Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life.

Cowan RA, Suidan RS, Andikyan V, Rezk YA, Einstein MH, Chang K, Carter J, Zivanovic O, Jewell EJ, Abu-Rustum NR, Basch E, Chi DS.

Gynecol Oncol. 2016 Nov;143(2):362-366. doi: 10.1016/j.ygyno.2016.08.335. Epub 2016 Sep 13.

34.

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.

Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL.

Gynecol Oncol. 2016 Dec;143(3):460-465. doi: 10.1016/j.ygyno.2016.10.016. Epub 2016 Oct 12.

35.

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ.

Gynecol Oncol. 2016 Dec;143(3):496-503. doi: 10.1016/j.ygyno.2016.09.014. Epub 2016 Sep 28.

36.

VALPROATE, BIPOLAR DISORDER AND POLYCYSTIC OVARIAN SYNDROME.

Okanović M, Zivanović O.

Med Pregl. 2016 Mar-Apr;69(3-4):121-6. Review.

PMID:
27506102
37.

Corrigendum to "Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center" [Gynecol. Oncol. 142 (2016) 13-18].

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, Long Roche K, Sonoda Y, Chi DS, O'Cearbhaill RE.

Gynecol Oncol. 2016 Oct;143(1):225. doi: 10.1016/j.ygyno.2016.07.097. Epub 2016 Aug 3. No abstract available.

PMID:
27496397
38.

Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.

Tseng JH, Suidan RS, Zivanovic O, Gardner GJ, Sonoda Y, Levine DA, Abu-Rustum NR, Tew WP, Chi DS, Long Roche K.

Gynecol Oncol. 2016 Aug;142(2):217-24. doi: 10.1016/j.ygyno.2016.05.035. Epub 2016 Jun 4.

39.

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, Long Roche K, Sonoda Y, Chi DS, O'Cearbhaill RE.

Gynecol Oncol. 2016 Jul;142(1):13-18. doi: 10.1016/j.ygyno.2016.05.015. Epub 2016 May 21. Erratum in: Gynecol Oncol. 2016 Oct;143(1):225.

40.

Introducing Hyperthermic Intraperitoneal Chemotherapy into Gynecological Oncology Practice - Feasibility and Safety Considerations: Single-Center Experience.

Abramian A, Zivanovic O, Kuhn W, Weber S, Schaefer N, Keyver-Paik MD, Kiefer N.

Oncol Res Treat. 2016;39(4):178-84. doi: 10.1159/000445180. Epub 2016 Mar 23.

PMID:
27160457
41.

Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery.

Eriksson AG, Montovano M, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, Barakat RR, Brown CL, Levine DA, Sonoda Y, Leitao MM Jr, Jewell EL.

Ann Surg Oncol. 2016 Aug;23(8):2522-8. doi: 10.1245/s10434-016-5134-2. Epub 2016 Feb 23.

42.

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.

43.

Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer.

Schiavone MB, Bielen MS, Gardner GJ, Zivanovic O, Jewell EL, Sonoda Y, Barakat RR, Chi DS, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol. 2016 Mar;140(3):383-6. doi: 10.1016/j.ygyno.2016.01.010. Epub 2016 Jan 8.

44.

Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer.

Leitao MM, Narain WR, Boccamazzo D, Sioulas V, Cassella D, Ducie JA, Eriksson AG, Sonoda Y, Chi DS, Brown CL, Levine DA, Jewell EL, Zivanovic O, Barakat RR, Abu-Rustum NR, Gardner GJ.

Ann Surg Oncol. 2016 Jul;23(7):2192-8. doi: 10.1245/s10434-015-5062-6. Epub 2016 Jan 7.

45.

Is It Time to Centralize Ovarian Cancer Care in the United States?

Cowan RA, O'Cearbhaill RE, Gardner GJ, Levine DA, Roche KL, Sonoda Y, Zivanovic O, Tew WP, Sala E, Lakhman Y, Vargas Alvarez HA, Sarasohn DM, Mironov S, Abu-Rustum NR, Chi DS.

Ann Surg Oncol. 2016 Mar;23(3):989-93. doi: 10.1245/s10434-015-4938-9. Epub 2015 Oct 28. Review.

46.

Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer.

Oseledchyk A, Zivanovic O.

Oncology (Williston Park). 2015 Sep;29(9):695-701. Review.

47.

Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Suidan RS, Leitao MM Jr, Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, Levine DA, Jewell EL, Brown CL, Abu-Rustum NR, Charlson ME, Chi DS.

Gynecol Oncol. 2015 Aug;138(2):246-51. doi: 10.1016/j.ygyno.2015.05.034. Epub 2015 May 31.

48.

Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, Alektiar KM, Makker V, Iasonos A, Abu-Rustum NR.

Ann Surg Oncol. 2016 Jan;23(1):196-202. doi: 10.1245/s10434-015-4612-2. Epub 2015 May 21.

49.

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O.

Int J Gynecol Cancer. 2015 May;25(4):599-606. doi: 10.1097/IGC.0000000000000389.

50.

Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma.

Kübler K, Ayub TH, Weber SK, Zivanovic O, Abramian A, Keyver-Paik MD, Mallmann MR, Kaiser C, Serçe NB, Kuhn W, Rudlowski C.

Gynecol Oncol. 2014 Nov;135(2):176-83. doi: 10.1016/j.ygyno.2014.08.028. Epub 2014 Aug 27.

PMID:
25173585

Supplemental Content

Loading ...
Support Center